<?xml version="1.0" encoding="UTF-8"?>
<p>Considering the sudden onset of the SARS-CoV-2 pandemic, countries struggled to quickly find a possible treatment to prevent respiratory failures and deaths, especially among patients with respiratory comorbidities. Also, since its fatal dynamics, there is no time to carry out new drug development in the traditional manner. Therefore, screening for already available drugs (for any activity against SARS-CoV-2) [
 <xref rid="B13" ref-type="bibr">13</xref>] is usually preferred in the first instance. It seems that an antiviral used for HIV infection, composed of two protease inhibitors (lopinavir and ritonavir), would have a therapeutic effect on coronavirus infections. It seems to have entered as a recommendation in the treatment of the COVID-19 in a short time [
 <xref rid="B13" ref-type="bibr">13</xref>]. Other compounds, such as redexivir, favivir, ribavirin, nitrazine, and chloroquine/hydroxychloroquine, are evaluated [
 <xref rid="B13" ref-type="bibr">13</xref>, 
 <xref rid="B68" ref-type="bibr">68</xref>]. Chloroquine and hydroxychloroquine have been shown to shorten the duration of SARS-CoV-2 viremia by reducing the viral load [
 <xref rid="B68" ref-type="bibr">68</xref>]. However, hydroxychloroquine has also been associated with a higher risk of nontuberculous mycobacterial (NTM) infection in rheumatoid arthritis patients [
 <xref rid="B14" ref-type="bibr">14</xref>].
</p>
